Background: Functional assessment is complex and often overlooked in patients with bipolar I disorder. The Functioning Assessment Short Test (FAST) assesses optimal functioning in these p...
Introduction
QUALIFY was a 28-week, randomized, open-label, rater-blinded, head-to-head study (NCT01795547) evaluating effectiveness of aripiprazole once-monthly (AOM 400) vs paliperidone...
Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults...
Introduction: Sexual dysfunction is a common side effect of antipsychotic treatment and may contribute to non-adherence. In the QUALIFY study (NCT01795547) the effectiveness of aripiprazo...
Background: Post-hoc analyses of the QUALIFY study (1), comparing effects of aripiprazole once-monthly (AOM 400) and paliperidone palmitate once-monthly (PP1M) treatment in patients with ...
Objective: To assess the efficacy and safety of Aripiprazole Once-Monthly (AOM 400) in preventing recurrence of mood episodes in patients with rapid and non-rapid cycling Bipolar I disord...
Background: The established role of oral aripiprazole in the treatment of Bipolar I disorder (BP-I) and the potential for a long-acting injectable formulation to improve adherence and pre...
Aims. To describe the background and clinical characteristics of patients who did versus those who did not have a recurrence of a mood episode during up to 52 weeks of maintenance treatme...